CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 4, 2009
Result type: Reports
Project Number: SR0191-000
Product Line: Reimbursement Review

Generic Name: Raltegravir

Brand Name: Isentress

Manufacturer: Merck Frosst Canada Ltd.

Therapeutic Area: HIV (treatment naïve)

Indications: HIV (treatment naïve)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 23, 2010

Recommendation Type: Do not list